ムロモナブ-CD3
参考資料

↑  “Individualized T cell monitored administration of ATG versus OKT3 in steroid-resistant kidney graft rejection”. Clinical Transplantation 17 (1):  69–74. (February 2003). doi:10.1034/j.1399-0012.2003.02105.x. PMID 12588325.
1 2 3 4 5 6  Mutschler, Ernst; Gerd Geisslinger; Heyo K. Kroemer; Monika Schäfer-Korting (2001) (ドイツ語). Arzneimittelwirkungen (8 ed.). Stuttgart: Wissenschaftliche Verlagsgesellschaft. p. 937. ISBN 3-8047-1763-2
↑  “muromonab-CD3”. Guide to Pharmacology.   IUPHAR/BPS. 21 August 2015閲覧。
↑  法人版, 日経バイオテクONLINE. “国内初の抗体医薬「オルソクローンOKT3」、製造販売を終了へ”. 日経バイオテクONLINE 法人版：日経BP Pharma Business. 2021年5月7日閲覧。
1 2  “経過措置医薬品告示情報｜情報で医療をささえる　データインデックス株式会社”. www.data-index.co.jp. 2021年5月7日閲覧。
1 2  Smith, S. L. (1996). “Ten years of Orthoclone OKT3 (muromonab-CD3): a review”. Journal of Transplant Coordination 6 (3):  109–119; quiz 119–1. doi:10.7182/prtr.1.6.3.8145l3u185493182. PMID 9188368.
↑  Abdi, Reza; Spencer Martin; Steven Gabardi (2009). “Immunosuppressive Strategies in Human Renal Transplantation – Induction Therapy”. Nephrology Rounds 7 (4). http://www.nephrologyrounds.org/crus/304-072.pdf 11 November 2012閲覧。. [リンク切れ]
↑  Mahmud, Nadim; Dusko Klipa; Nasimul Ahsan (2010). “Antibody immunosuppressive therapy in solid-organ transplant Part 1”. mAbs 2 (2):  148–156. doi:10.4161/mabs.2.2.11159. PMC 2840233. PMID 20150766. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840233/.
↑  “国立医薬品食品衛生研究所 生物薬品部”. www.nihs.go.jp. 2021年5月7日閲覧。
1 2 3 4 5  “Orthoclone OKT3”. Professional Drug Information.   Drugs.com. 3 January 2010閲覧。
↑  “Therapy with OKT3 monoclonal antibody in refractory T cell acute lymphoblastic leukemia induces interleukin-2 responsiveness”. Leukemia 9 (3):  382–90. (March 1995). PMID 7885036.
1 2 3  Rich, Robert (2013). Clinical immunology : principles and practice (4th ed.). London: Elsevier. ISBN 978-0-7234-3710-9. OCLC 823736017. https://www.sciencedirect.com/book/9780723436911/clinical-immunology
↑  Sgro, C. (1995-12-20). “Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review” (英語). Toxicology. Immunotoxicology Papers presented at the Third Summer School in Immunotoxicology 105 (1):  23–29. doi:10.1016/0300-483X(95)03123-W. ISSN 0300-483X. PMID 8638282. https://doi.org/10.1016%2F0300-483X%2895%2903123-W.
1 2 3  Bhorade, S. M.; Stern, E. (2009-01-15). “Immunosuppression for Lung Transplantation”. Proceedings of the American Thoracic Society 6 (1):  47–53. doi:10.1513/pats.200808-096go. ISSN 1546-3222. PMID 19131530. https://doi.org/10.1513/pats.200808-096go.
↑  Benekli, M.; Hahn, T.; Williams, B. T.; Cooper, M.; Roy, H. N.; Wallace, P.; Stewart, C.; Bambach, B. et al. (September 2006). “Muromonab-CD3 (Orthoclone OKT3 ® ), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation” (英語). Bone Marrow Transplantation 38 (5):  365–370. doi:10.1038/sj.bmt.1705450. ISSN 1476-5365. PMID 16862164. https://www.nature.com/articles/1705450.
↑  Abramowicz, D.; Schandene, L.; Goldman, M.; Crusiaux, A.; Vereerstraeten, P.; De Pauw, L.; Wybran, J.; Kinnaert, P. et al. (1989). “Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients”. Transplantation 47 (4):  606–608. doi:10.1097/00007890-198904000-00008. PMID 2523100.